Pemphigoid

Summary

Pemphigoid (MONDO:0850301) is a disease and 5 clinical trials. Top therapeutic interventions include ixekizumab and powdered cellulose. A subtype of autoimmune bullous skin disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pemphigoid
Mondo ID	MONDO:0850301
DOID	DOID:0080841
ICD-10-CM	L12
ICD-11	445309625
SNOMED CT	86142006
GARD	0026598
Is cancer (heuristic)	no

Data availability: 12 cell lines.

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › autoimmune bullous skin disease › pemphigoid

Related subtypes (10): pemphigus, subcorneal pustular dermatosis, dermatitis herpetiformis, anti-p200 pemphigoid, mucous membrane pemphigoid, acquired epidermolysis bullosa, linear IgA Dermatosis, paraneoplastic pemphigus, bullous pemphigoid, IgA pemphigus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03099538	PHASE2	COMPLETED	Ixekizumab in the Treatment of Bullous Pemphigoid
NCT05520086	PHASE1/PHASE2	UNKNOWN	Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
NCT02365675	Not specified	UNKNOWN	Wound Dressings for Pemphigus and Pemphigoid
NCT02823067	Not specified	COMPLETED	Pruritus and Pemphigoid in Nursing Home Patients
NCT04555681	Not specified	COMPLETED	Study of the Periodontal Microbiota in Gingival Cicatricial Pemphigoid Patients. Bicentric Pilot Study.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IXEKIZUMAB	4	1
POWDERED CELLULOSE	3	1